'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?

'Takeover Fever' in biotech land is sure to continue today after Facet Biotech Corporation (Nasdaq: FACT) agreed to be acquired by Abbott (NYSE: ABT) for $27 per share, which is a 67% premium to yesterday's close and a 54% premium to a rejected $17.50 bid last year from Biogen Idec (Nasdaq: BIIB).

Last night's deal also follows Astellas Pharma's recent $52 per share bid for OSI Pharmaceuticals Inc. (NASDAQ: OSIP), which was rejected. A higher bid is expected for OSI.

So who's next? Below are some biotech companies recently mentioned as takeover bait in the sector:

• Onyx Pharmaceuticals Inc. (Nasdaq: ONXX)
  
• Genzyme Corp. (Nasdaq: GENZ)
  
• Biogen Idec (Nasdaq: BIIB)
  
• Human Genome Sciences Inc. (Nasdaq: HGSI)
  
• Dendreon Corp. (Nasdaq: DNDN)
  
• Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN)
  
• Alkermes, Inc. (Nasdaq: ALKS)
  
• Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA)
  
• Acorda Therapeutics, Inc. (Nasdaq: ACOR)
  
• Affymax, Inc. (Nasdaq: AFFY)
  
• Cytokinetics Inc. (Nasdaq: CYTK)
  
• Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH)
  
• BioMarin Pharmaceutical Inc. (Nasdaq: BMRN)
  
• ISIS Pharmaceuticals Inc. (NASDAQ: ISIS)

You May Also Be Interested In

• Syntec Optics added to Russell 3000 index
• OptimizeRx names Sarah Bast as chief marketing officer
• Agility Robotics names new CFO ahead of planned public listing